The cost-effectiveness of rotavirus vaccination in Armenia

Vaccine

Volumn 29, Issue 48, 2011, Pages 9104-9111

  Jit, Mark ^a   Yuzbashyan, Ruzanna ^b   Sahakyan, Gayane ^c   Avagyan, Tigran ^d   Mosina, Liudmila ^d  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Ministry of Health   (Armenia)

^c Ministry of Health   (Armenia)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Armenia; Cost effectiveness; Rotavirus; Vaccine

Indexed keywords

ROTAVIRUS VACCINE;

ARMENIA; ARTICLE; CHILD; CONSULTATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INCIDENCE; INFANT; MEDICAL CARE; NONHUMAN; PRIMARY HEALTH CARE; PRIORITY JOURNAL; ROTAVIRUS; ROTAVIRUS INFECTION; VACCINATION;

ARMENIA; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; INFANT; MODELS, ECONOMIC; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SENTINEL SURVEILLANCE; VACCINATION; VACCINES, ATTENUATED;

EID: 82455192273     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.127     Document Type: Article

References (38)

1. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A., Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003, 9(May (5)):565-572.
2. World Health Organization Estimated deaths for children under 5 years of age 2010, Available at: http://www.who.int/immunization_monitoring/burden/rotavirus_estimates/en/index.html [accessed on 1.11.10].
3. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370(November (9601)):1757-1763.
4. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(January (1)):23-33.
5. Rotavirus vaccines WHO position paper. Wkly Epidemiol Rec 2007, 82(August (32)):285-295.
6. Rotavirus vaccines: an update. Wkly Epidemiol Rec 2009, 84(December (51-52)):533-537.
7. Jit M., Bilcke J., Mangen M.J., Salo H., Melliez H., Edmunds W.J., et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009, 27(October (44)):6121-6128.
8. Jit M., Mangen M.J., Melliez H., Yazdanpanah Y., Bilcke J., Salo H., et al. An update to " the cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe" Vaccine 2010, 28(November (47)):7457-7459.
9. Adams T., Baltussen R., Tan-Torres T., Evans D., Hutubessy R., Acharya A., Murray C.J.L. Making Choices in Health. WHO Guide to Cost-Effectiveness Analysis 2003, World Health Organisation, Geneva.
10. PATH Accelerating the introduction of rotavirus vaccines into GAVI-eligible countries. Investment case for GAVI secretariat October, 2006, Available from: http://www.gavialliance.org/resources/Rotavirus_Investment_Case_Oct06.pdf [accessed on 10.10.10].
11. World Health Organization WHO global health observatory 2010, Available from: http://apps.who.int/ghodata/ [accessed on 15.10.10].
12. Samoilovich E.O. Sub-regional rotavirus laboratory: the results of NL external quality control and rotavirus genotyping. Presented at the meeting on the epidemiology and prevention of rotaviurs disease in the NIS 2010.
13. World Health Organization WHO and UNICEF estimates of national immunization coverage 2010, Available from: http://www.who.int/immunization_monitoring/data/arm.pdf [accessed on 10.10.10].
14. World Health Organization World health statistics 2008, Available from: http://www.who.int/whosis/whostat/2008/en/index.html [accessed on 10.10.10].
15. Linhares A.C., Velazquez F.R., Perez-Schael I., Saez-Llorens X., Abate H., Espinoza F., et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008, 371(April (9619)):1181-1189.
16. Kim S.Y., Sweet S., Slichter D., Goldie S.J. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Pub Health 2010, 10:253.
17. National Statistical Service of the Republic of Armenia Demographic handbook of Armenia 2009, Available at: http://www.armstat.am/file/article/demos_09_2.pdf [accessed on 1.11.10].
18. Williams C.J., Lobanov A., Pebody R.G. Estimated mortality and hospital admission due to rotavirus infection in the WHO European region. Epidemiol Infect 2009, 137(May (5)):607-616.
19. World Bank Mortality rate, under-5 (per 1,000) 2010, Available from: http://data.worldbank.org/indicator/SH.DYN.MORT/countries/AM-7E-XN [accessed on 1.11.10].
20. World Health Organization Regional Office for Europe European health for all database (HFA-DB) 2010, Available from http://data.euro.who.int/hfadb/ [accessed on 1.11.10].
21. Bilcke J., Van Damme P., Van Ranst M., Hens N., Aerts M., Beutels P. Estimating the incidence of symptomatic rotavirus infections: a systematic review with meta-analysis. PLoS One 2009, 4(June (6)):e6060.
22. Armenia 2005: results from the Demographic and Health Survey. Stud Fam Plann 2008, 39(September (3)):221-226.
23. World Health Organization The treatment of diarrhoea. A manual for physicians and other senior health workers 2010, Available at: http://whqlibdoc.who.int/publications/2005/9241593180.pdf [accessed on 1.11.10].
24. Murray C.J.L., Lopez ADe. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and. risk factors in 1990 and projected to 2020 1996, World Health Organization.
25. World Health Organization CHOosing Interventions that are Cost Effective (WHO-CHOICE). Estimates of unit costs for patient services for Armenia 2010, Available at: http://www.who.int/choice/country/arm/cost/en/index.html [accessed on 1.11.10].
26. National Statistical Service of the Republic of Armenia Statistical yearbook of Armenia 2009, Available at: http://www.armstat.am/file/doc/99458068.pdf [accessed on 1.11.10].
27. National Statistical Service of the Republic of Armenia Marzes of the republic of Armenia and Yerevan city in figures 2010, Available at: http://www.armstat.am/file/article/marz_10_22.pdf [accessed on 1.11.10].
28. Bilcke J., Van Damme P., Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and " no medical care" disease impact in Belgium. Med Decis Making 2009, (January-Februrary (1)):33-50.
29. National Statistical Service of the Republic of Armenia Report on labour force and informal employment in Armenia (on the results of one-off sample survey) 2010, Available at: http://www.armstat.am/en/?nid=81&id=1008 [accessed on 1 November 2010].
30. Murray C.J.L. Rethinking DALYs. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020 1996, Harvard School of Public Health on behalf of The World Health Organization and The World Bank. C.J.L. Murray, A.D. Lopez (Eds.).
31. GAVI alliance GAVI welcomes lower prices for life-saving vaccines 2011, http://www.gavialliance.org/media_centre/press_releases/vaccine_prices.php [accessed on 15.07.11].
32. Atherly D., Dreibelbis R., Parashar U.D., Levin C., Wecker J., Rheingans R.D. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J Infect Dis 2009, 200(November (Suppl. 1)):S28-S38.
33. Isakbaeva E.T., Musabaev E., Antil L., Rheingans R., Juraev R., Glass R.I., et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 2006, (August).
34. Knies S., Severens J.L., Ament A.J., Evers S.M. The transferability of valuing lost productivity across jurisdictions. differences between national pharmacoeconomic guidelines. Value Health 2010, 13(August (5)):519-527.
35. Goldie S.J., O'Shea M., Campos N.G., Diaz M., Sweet S., Kim S.Y. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008, 26(July (32)):4080-4093.
36. Sinha A., Levine O., Knoll M.D., Muhib F., Lieu T.A. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007, 369(February (9559)):389-396.
37. Tate J.E., Patel M.M., Steele A.D., Gentsch J.R., Payne D.C., Cortese M.M., et al. Global impact of rotavirus vaccines. Expert Rev Vaccines 2010, 9(April (4)):395-407.
38. de Blasio B.F., Kasymbekova K., Flem E. Dynamic model of rotavirus transmission and the impact of rotavirus vaccination in Kyrgyzstan. Vaccine 2010, 28(November (50)):7923-7932.